LIVMARLI

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Apr 10, 2025

   1 yr 3 mo ago

2. Today

3. Exclusivity ends · NCE

   New chemical entity exclusivity (5 years)

   Sep 29, 2026

   in 3 mo

4. Exclusivity ends · I-938

   New indication exclusivity (3 years)

   Mar 13, 2027

   in 9 mo

5. Patent 11260053 expires

   Listed method-of-use patent (U-4187) expiration.

   May 26, 2031

   in 5 yr

6. Patent 10512657 expires

   Listed method-of-use patent (U-4186) expiration.

   Oct 26, 2032

   in 6 yr 5 mo

7. Patent 11229661 expires

   Listed method-of-use patent (U-4186) expiration.

   Oct 26, 2032

   in 6 yr 5 mo

8. Patent 11376251 expires

   Listed method-of-use patent (U-4187) expiration.

   Oct 26, 2032

   in 6 yr 5 mo

9. Patent 12350267 expires

   Listed method-of-use patent (U-3973) expiration.

   Oct 26, 2032

   in 6 yr 5 mo

10. Patent 11229647 expires

    Listed method-of-use patent (U-4187) expiration.

    Feb 12, 2040

    in 13 yr 10 mo

11. Patent 11497745 expires

    Listed method-of-use patent (U-4187) expiration.

    Feb 12, 2040

    in 13 yr 10 mo

12. Patent 12296050 expires

    Listed drug product patent expiration.

    Oct 05, 2043

    in 17 yr 7 mo

13. Patent 12296050 expires

    Listed drug product patent expiration.

    Oct 05, 2043

    in 17 yr 7 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

• LIVMARLIBrand (NDA)

  NDA 214662 · MIRUM

  2021

Marketing exclusivity (2)

• NCENew chemical entity exclusivity (5 years)

  Sep 29, 2026

  in 3 mo

• I-938New indication exclusivity (3 years)

  Mar 13, 2027

  in 9 mo

Listed patents (9)